ADMA Biologics (NASDAQ:ADMA) Releases Earnings Results, Hits Estimates

ADMA Biologics (NASDAQ:ADMA) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16, FiscalAI reports. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. During the same period last year, the company posted $0.14 earnings per share. The business’s quarterly revenue was up 2.0% on a year-over-year basis.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV momentum accelerated: Second-quarter revenue rose 24% year over year to $102.9 million, with June showing the strongest sequential end-user utilization growth since the first half of 2024. Management attributed the trend to increased physician adoption, new patient starts, broader payer engagement, and supporting real-world evidence.
• Profitability and cash generation improved: Revenue increased 2% year over year to $124.4 million, while gross margin expanded to 69% from 55% and adjusted EBITDA rose 22% to $61.8 million, supported by ASCENIV mix and manufacturing efficiencies.
• BIVIGAM remains under pressure: Although demand and revenue improved sequentially as market conditions stabilized, management still expects BIVIGAM revenue to decline approximately 40%–50% from 2025 levels amid excess standard immunoglobulin supply, discounting, and competitive pressures.
• 2026 guidance was reiterated: ADMA continues to forecast revenue of $530 million–$560 million, adjusted EBITDA of $265 million–$300 million, and adjusted net income of $170 million–$200 million, while stating it remains confident in meeting or exceeding those expectations.
• Capital allocation and pipeline progress continued: The company repurchased approximately 7.1 million shares in the quarter and remains on track for at least $200 million of 2026 buybacks. SG-001 is advancing toward conformance lot production in the second half of 2026 and a planned FDA pre-IND meeting package submission by year-end, with management estimating a potential $300 million–$500 million annual opportunity if approved.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $9.26 on Thursday. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $20.46. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 13.62 and a beta of 0.74. The company has a fifty day moving average price of $8.55 and a 200-day moving average price of $11.37.

Analysts Set New Price Targets

Several analysts have recently commented on ADMA shares. Mizuho reduced their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ADMA Biologics has an average rating of “Hold” and a consensus price target of $18.67.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported second-quarter revenue of $124.4 million, up 2% year over year, while GAAP net income rose 11% to $37.8 million. Adjusted EBITDA increased 22% to $61.8 million, supporting the company’s profitability profile. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly EPS met the $0.16 analyst consensus, and ASCENIV revenue climbed 24% to $102.9 million. Management also said BIVIGAM demand and revenue stabilized sequentially, indicating improving utilization trends. ADMA Biologics Q2 Earnings Snapshot
• Positive Sentiment: The company reiterated 2026 revenue guidance of $530 million to $560 million, broadly consistent with the $534.9 million consensus estimate, and is targeting more than $200 million in share repurchases. Buybacks could provide demand for the stock and increase per-share value if executed. ADMA Reiterates 2026 Guidance and Targets Share Repurchases
• Neutral Sentiment: Management highlighted new real-world evidence on ASCENIV’s patient outcomes and healthcare-resource utilization, potentially supporting longer-term demand, although the evidence remains an upcoming catalyst rather than a reported financial result.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action covering investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. The complaints allege misleading statements involving revenue, financial condition, inventory distribution and business practices. Lead-plaintiff notices cite an August 10 deadline. The allegations have not been proven, but the litigation creates legal costs, reputational risk and potential financial exposure. ADMA Securities Fraud Lawsuit Notice

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $29,000. iSAM Funds UK Ltd purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $34,000. EverSource Wealth Advisors LLC raised its stake in shares of ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,180 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 700 shares during the period. Finally, Kestra Advisory Services LLC purchased a new position in shares of ADMA Biologics in the 4th quarter worth about $72,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.